$Autolus Therapeutics (AUTL.US)$ First regulatory approval validates Autolus' technology platform and establishes commercial pathway, though NICE approval remains critical next step. This MHRA conditional authorization represents a transformative milestone for Autolus Therapeutics, validating both their lead product and underlying technology platform. As the company's first regulatory approval, it establishes Autolus as an emerging commercial-stage biopharmaceutic...
$Autolus Therapeutics (AUTL.US)$ MHRA approval of AUCATZYL for r/r B-ALL represents significant treatment advance with impressive 76.6% response rate and manageable safety profile. The MHRA's conditional authorization of AUCATZYL marks a critical advancement for adult patients with r/r B-ALL, a disease with historically poor outcomes. The FELIX study results are compelling, showing a 76.6% complete response rate in the pivotal cohort, with 21.2 months median response dur...
$Autolus Therapeutics (AUTL.US)$Autolus Therapeutics to Present Key Data on AUCATZYL At 2025 Tandem Meetings, Highlighting Cost Benefits and Clinical Outcomes! February 12 to 15, 2025
$Autolus Therapeutics (AUTL.US)$ Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
$Autolus Therapeutics (AUTL.US)$Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 6 to 8 PM pst 12/9/24! 4 MINUTES AGO, 7:30 PM EST VIA GLOBENEWSWIRE
Daily Investors
:
Now they had their PDUFA Meetings, but that's the risk we try. It's always better for nothing, then to get a major disappointment and catastrophic loss
Trytosaveabit
:
Not sure how it performs compared to GILEAD’S TECARTUS? Do you know? Is it better? Safer? Cheaper? I didn’t get to deep in the data! But you are my Dr so ima ask you first!
Trytosaveabit
Jaguar8
OP
:
Oh brother thank you! But please you ain’t gotta do that! I was just figuring you may have already had some info about the drug that’s all! Please don’t trouble yourself! Just rest up please!
Jaguar8
OPTrytosaveabit
:
So Aucatzyl has overall complete remission of 63% compared to 62% of Tecartus. Aucatzyl has no picing yet but Tecartus is 373,000 USD per infusion
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Autolus Therapeutics Stock Discussion
First regulatory approval validates Autolus' technology platform and establishes commercial pathway, though NICE approval remains critical next step.
This MHRA conditional authorization represents a transformative milestone for Autolus Therapeutics, validating both their lead product and underlying technology platform. As the company's first regulatory approval, it establishes Autolus as an emerging commercial-stage biopharmaceutic...
MHRA approval of AUCATZYL for r/r B-ALL represents significant treatment advance with impressive 76.6% response rate and manageable safety profile.
The MHRA's conditional authorization of AUCATZYL marks a critical advancement for adult patients with r/r B-ALL, a disease with historically poor outcomes. The FELIX study results are compelling, showing a 76.6% complete response rate in the pivotal cohort, with 21.2 months median response dur...
Revolutionary Leukemia Treatment: Autolus's CAR-T Therapy Secures First-Ever UK Approval with 77% Success Rate
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics (NASDAQ: AUTL)presented clinical data updates at ASH 2024, featuring one oral and three poster presentations about obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
The FELIX trial demonstrated that obe-cel treatment achieved deep molecular remission in 84% of responde...
4 MINUTES AGO, 7:30 PM EST
VIA GLOBENEWSWIRE
ya I'm getting in here
No comment yet